PURPOSE: To examine the incidence of urinary tract infection (UTI) after flexible cystoscopy (FC) and determine whether prophylactic norfloxacin reduces this incidence compared with placebo. PATIENTS AND METHODS: A double-blind trial was performed, randomizing 234 patients to either 400 mg ofnorfloxacin or placebo prior to FC. All patients provided a midstream urine specimen (MSU) before the procedure, as well as at day 3 and day 7 after FC. In addition, a telephone questionnaire was performed to correlate the nature and severity of any symptoms associated with UTI. RESULTS: Interim analysis was performed because of the low recruitment rate, and a significantly lower infection rate than expected meant that the trial was discontinued. There was one symptomatic UTI in the placebo group (0.82%) and one in the norfloxacin group (0.89%). The UTI in the placebo group was de novo, while the infection in the norfloxacin group was secondary to pre-FC bacteriuria. There was no difference in the infection rates in the two groups. The overall infection rate (de novo and secondary to existing bacteruria) after FC was 0.85%. CONCLUSION: Infection after flexible cystoscopy is rare and not associated with significant morbidity. A much larger study would be required to determine whether antibiotic prophylaxis significantly reduces the rate of postprocedure UTI.
RCT Entities:
PURPOSE: To examine the incidence of urinary tract infection (UTI) after flexible cystoscopy (FC) and determine whether prophylactic norfloxacin reduces this incidence compared with placebo. PATIENTS AND METHODS: A double-blind trial was performed, randomizing 234 patients to either 400 mg of norfloxacin or placebo prior to FC. All patients provided a midstream urine specimen (MSU) before the procedure, as well as at day 3 and day 7 after FC. In addition, a telephone questionnaire was performed to correlate the nature and severity of any symptoms associated with UTI. RESULTS: Interim analysis was performed because of the low recruitment rate, and a significantly lower infection rate than expected meant that the trial was discontinued. There was one symptomatic UTI in the placebo group (0.82%) and one in the norfloxacin group (0.89%). The UTI in the placebo group was de novo, while the infection in the norfloxacin group was secondary to pre-FC bacteriuria. There was no difference in the infection rates in the two groups. The overall infection rate (de novo and secondary to existing bacteruria) after FC was 0.85%. CONCLUSION: Infection after flexible cystoscopy is rare and not associated with significant morbidity. A much larger study would be required to determine whether antibiotic prophylaxis significantly reduces the rate of postprocedure UTI.
Authors: Steeve Doizi; Guido Kamphuis; Guido Giusti; J L Palmero; J M Patterson; Silvia Proietti; Michael Straub; Jean de la Rosette; Olivier Traxer Journal: World J Urol Date: 2016-12-17 Impact factor: 4.226
Authors: Magnus Grabe; Henry Botto; Mete Cek; Peter Tenke; Florian M E Wagenlehner; Kurt G Naber; Truls E Bjerklund Johansen Journal: World J Urol Date: 2011-07-22 Impact factor: 4.226
Authors: Lieschen H Quiroz; S Abbas Shobeiri; Mikio A Nihira; Jordan Brady; Robert A Wild Journal: Int Urogynecol J Date: 2012-05-09 Impact factor: 2.894
Authors: Justin R Gregg; Caroline L Kang; Thomas R Talbot; Derek Moore; S Duke Herrell; Roger Dmochowski; Daniel A Barocas Journal: Urol Pract Date: 2016-10-22
Authors: Jason R Gee; Bradley J Waterman; David F Jarrard; Sean P Hedican; Reginald C Bruskewitz; Stephen Y Nakada Journal: JSLS Date: 2009 Apr-Jun Impact factor: 2.172